Cadrenal Therapeutics, Inc. (CVKD) Form 8-K — Jun 3, 2026
Cadrenal Therapeutics announced the mutual departure of CFO Matthew K. Szot effective May 28, 2026, with CEO Quang X. Pham assuming the role of interim CFO and Principal Accounting Officer. The company entered into a separation agreement with Szot on June 3, 2026, providing for a total cash payout of approximately $603,709, comprising $365,806 in severance and $237,903 in accrued bonus, paid in installments over several months.
Key figures
- Accrued Bonus
- 237903
- Severance Payment
- 365806
- Bonus Installments
- 2
- Revocation Period Days
- 7
- Severance Installments
- 4
Price after filing
1 day: +2.9%7 days: -1.2%30 days: -14.1%
Close on the filing date to close N calendar days later (from $4.19). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.